"Given Merck KGaA’s existing franchise in oncology, which constitutes about 25% of its healthcare sales in 2024, we see the potential acquisition of SpringWorks as likely complementary and ...

Merck KGaA (MKGAY) confirms “advanced discussions” with Springworks Therapeutics (SWTX) regarding a potential acquisition. “Merck also confirms ...

Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare diseases drugmaker soaring. One of SpringWorks’ drugs, Ogsiveo ...

SpringWorks Therapeutics ( NASDAQ: SWTX) soared ~40% after a report that Merck KGaA ( OTCPK:MKGAF) is in advanced discussions ...

Die Merck KGaA befindet sich in fortgeschrittenen Verhandlungen zum Kauf des amerikanischen Krebsspezialisten SpringWorks Therapeutics. Das Portfolio des Unternehmens umfasst unter anderen das ...

Germany’s Merck KGaA is in advanced talks to acquire SpringWorks, Reuters first reported Monday, citing people close to the matter. After the report, Merck KGaA later confirmed (PDF) the ...

Update 2:15pm: Adds Merck KGaA confirmation. SpringWorks Therapeutics (NASDAQ:SWTX) soared ~40% after a report that Merck KGaA (OTCPK:MKGAF) is in advanced discussions to acquire the cancer and ...

Merck KGaA , the German healthcare and technology group, said on Monday it is in advanced talks to acquire U.S. cancer and rare diseases drugmaker SpringWorks Therapeutics . Germany's Merck in ...

Germany's Merck KGaA is in advanced talks to buy U.S. cancer and rare diseases biotech company Springworks Therapeutics, Reuters says, citing unnamed sources. -- The deal could be finalized in the ...

NEW YORK/FRANKFURT (Reuters) - Merck KGaA, the German healthcare and technology group, said on Monday it is in advanced talks to acquire U.S. cancer and rare diseases drugmaker SpringWorks ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...